MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$28,028K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Stock-based compensation
Accounts payable
Depreciation expense
Others
Negative Cash Flow Breakdown
Net loss
Deferred revenue
Accrued expense and other liabil...
Purchases of property and equipm...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-30,359
-28,666
-22,977
-35,710
Depreciation expense
699
693
723
767
Accretion of marketable securities
-
-
-55
-291
Non-cash interest expense related to loan payable
-
-
462
-
Non-cash interest expense related to note payable
125
-222
-
118
Stock-based compensation
2,357
2,465
2,008
3,011
Loss on disposal of property and equipment
-99
-
-
-
Prepaid expenses and other assets
-483
-126
903
-867
Right-of-use assets and lease liabilities, net
9
16
91
463
Accounts payable
843
1,045
-5,067
1,933
Accrued expense and other liabilities
-740
904
-3,375
-1,110
Deferred revenue
-1,051
-982
-2,567
-2,512
Net cash used in operating activities
-27,535
-24,279
-32,002
-32,464
Purchases of property and equipment
493
70
171
1,425
Purchases of marketable securities
-
-
0
-1
Proceeds from maturities of marketable securities
-
-
15,000
34,000
Proceeds from sale of property and equipment
28
-
-
-
Net cash (used in) provided by investing activities
-465
-70
14,829
32,576
Proceeds from issuance of common stock under employee stock purchase plan
99
-
73
0
Cash paid for debt issuance costs
-
-
0
0
Cash paid for financing costs
-
-
0
0
Net cash provided by (used in) financing activities
99
-
73
0
Net increase (decrease) in cash, cash equivalents and restricted cash
-27,901
-24,349
-17,100
112
Cash, cash equivalents, and restricted cash - beginning of period
133,088
157,437
174,537
183,720
Cash, cash equivalents, and restricted cash - end of period
105,187
-
-
-
Cash and cash equivalents
100,156
-
-
-
Restricted cash
5,031
-
-
-
Total cash, cash equivalents, and restricted cash
105,187
133,088
157,437
174,537
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock under...
$99K
(-48.17%↓ Y/Y)
Net cash provided by
(used in) financing...
$99K
(124.21%↑ Y/Y)
Net increase
(decrease) in cash, cash...
-$27,901K
(-200.17%↓ Y/Y)
Canceled cashflow
$99K
Stock-based compensation
$2,357K
(-64.75%↓ Y/Y)
Accounts payable
$843K
(585.37%↑ Y/Y)
Depreciation expense
$699K
(-49.20%↓ Y/Y)
Prepaid expenses and
other assets
-$483K
(-198.77%↓ Y/Y)
Non-cash interest
expense related to note...
$125K
(-44.20%↓ Y/Y)
Loss on disposal of
property and equipment
-$99K
Right-of-use assets and lease
liabilities, net
$9K
(-99.62%↓ Y/Y)
Proceeds from sale of
property and equipment
$28K
Net cash used in
operating activities
-$27,535K
(61.14%↑ Y/Y)
Net cash (used in)
provided by investing...
-$465K
(-100.75%↓ Y/Y)
Canceled cashflow
$4,615K
Canceled cashflow
$28K
Net loss
-$30,359K
(57.29%↑ Y/Y)
Purchases of property and
equipment
$493K
(-82.46%↓ Y/Y)
Deferred revenue
-$1,051K
(79.97%↑ Y/Y)
Accrued expense and
other liabilities
-$740K
(73.00%↑ Y/Y)
Buy us a coffee
TScan Therapeutics, Inc. (TCRX)
TScan Therapeutics, Inc. (TCRX)